Joan Walker, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1477521839
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,845 of the $10,514 with a category attached, or 84.1%. Merck accounts for 97.3% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $8,071 and has fallen 98.3% since, to $133 in 2025.
Across 32 payments — averaging $328.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$10K
- Eisai Inc.$52
- AstraZeneca$33
- Bard Peripheral Vascular, Inc.$25
- Astellas Pharma US Inc$22
- Tersera Therapeutics LLC$21
- plus $132 from 8 others
What the payments were for
- Consulting fees$8,84584%
- Travel & lodging$1,09210%
- Food & beverage$5655%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 16 | $10,229 |
| Eisai Inc. | 2 | $52 |
| AstraZeneca | 2 | $33 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $21 |
| Genmab U.S., Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Seagen Inc. | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Stemline Therapeutics Inc. | 1 | $13 |
| Clovis Oncology, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$942
How this compares
$10,514 in reported general payments places this provider in the 70th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 17 | $53,411 |
| EliquisApixaban | 25 | $13,584 |
| Letrozole | 20 | $550 |
| Duloxetine Hcl | 15 | $321 |
| Gabapentin | 20 | $301 |
| Ondansetron Hcl | 26 | $272 |
| Prochlorperazine Maleate | 21 | $179 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Oklahoma City
- Debra RichardsonOklahoma City$97K
- Camille JacksonOklahoma City$35K
- Tara CastellanoOklahoma City$26K
- Christina WashingtonOklahoma City$9K
- Elizabeth EvansOklahoma City$3K
- Lauren DockeryOklahoma City$3K
- Ana ValenteOklahoma City$2K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
- Aleia CrimOklahoma City$862
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.